Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Authors
Barlesi, FDrilon, A
De, BF
Cho, BC
Ahn, MJ
Siena, S
Krebs, Matthew G
Lin, CC
John, T
Tan, DSW
Seto, T
Dziadziuszko, R
Arkenau, HT
Rolfo, C
Wolf, J
Ye, C
Riehl, T
Eng, S
Doebele, RC
Affiliation
Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, FranceIssue Date
2019
Metadata
Show full item recordCitation
Barlesi F, Drilon A, De Braud F, Cho BC, Ahn MJ, Siena S, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Ann Oncol. 2019;30 Suppl 2:ii48-ii9.Journal
Annals of OncologyDOI
10.1093/annonc/mdz063.007PubMed ID
32131257Additional Links
https://dx.doi.org/10.1093/annonc/mdz063.007Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz063.007